Table 2.
Treatments and perioperative data.
| Period I (pre-COVID) | Period II (COVID) | p value | |
|---|---|---|---|
| N | |||
| Treatment/management | 125 | 216 | |
| Successful conservative treatment | 84 (67.2%) | 101 (46.8%) | < 0.001 |
| Percutaneous drainage | 16 (12.8%) | 52 (24.1%) | 0.012 |
| Primary + secondary | 3 + 13 | 32 + 20 | |
| Surgical treatment | 25 (20%) | 63 (29.2%) | NS |
| Primary + secondary | 21 + 4 | 58 + 5 | |
| Surgical treatment | |||
| Laparoscopic cholecystectomy | 19 (76%) | 49 (77.8%) | NS |
| Converted laparoscopic cholecystectomy | 4 (16%) | 13 (20.6%) | |
| Open cholecystectomy | 2 (8%) | 1 (1.6%) | |
| CR (%) | 17.4 | 20.9 | NS |
| LSR (%) | 76 | 77.78 | NS |
| Length of hospital stay | |||
| N | 117 | 201 | |
| NA | 8 | 15 | |
| Median (min–max) | 8 (1–62) | 7 (1–60) | 0.011 |
| Mortality | |||
| No | 116 (95.08%) | 198 (94.29%) | NS |
| Yes | 6 (4.92%) | 12 (5.71%) | |
| NA | 3 | 6 | |
| 30-day mortality | |||
| No | 113 (98.26%) | 192 (96.97%) | NS |
| Yes | 2 (1.74%) | 6 (3.03%) | |
| NA | 10 | 18 | |
| Unplanned readmission | |||
| No | 115 (100%) | 177 (93.65%) | 0.004 |
| Yes | 0 (0%) | 12 (6.35%) | |
| NA | 10 | 27 | |
CCY cholecystectomy, COVID coronavirus disease, CR conversion rate (number of converted laparoscopic cholecystectomies × 100/[total number of surgeries − number of primary open cholecystectomies]), LSR laparoscopic success rate (number of laparoscopic cholecystectomies/total number of surgeries), NA no data.